CFF Path to a Cure (PTAC) Research Grants

CFF Path to a Cure (PTAC) Research Grants sit under the Cystic Fibrosis Foundation's therapeutics arm and support academic work aimed at restoring CFTR function for patients who are not served by current modulators. The program is part of CFF's Path to a Cure initiative launched in 2019, and the emphasis is on gene repair, gene replacement, cell delivery, and tools that can measure CFTR restoration. It is a U.S. academic grant route for university-based investigators and research organizations rather than companies or individuals. Awards can reach $150,000 a year for up to two years, with 12% indirect costs on top, and the program runs on a May and December cycle. The eligibility profile points to non-profit and research organizations with university involvement, and the record flags pilot evidence as expected. The work is meant to be translational, with a strong preference for projects that can connect a delivery or editing concept to a credible assay or model. Applicants fit best when they can show a concrete route from mechanism to measurable CFTR restoration. CFF appears to use the award as a way to support earlier-stage academic ideas that can mature into larger therapeutic programs, so proposals need clear milestones, a workable experimental system, and a reason the approach can reach broad CF populations.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.